Retail Pharmacy in Brazil Porter's Six Forces Analysis¶
This report analyzes the competitive landscape of the retail pharmacy industry in Brazil through the lens of Porter's Six Forces framework, incorporating insights from the provided value chain analysis and recent market data from 2024 and 2025.
Competitive Rivalry¶
The Brazilian retail pharmacy market is characterized by intense competitive rivalry, driven by a significant number of players and the increasing consolidation among large chains. As of the end of 2024, there were 93.7 thousand pharmacies and drugstores operating in Brazil. [Value Chain Analysis, Industry Research] While this indicates a fragmented market at first glance, the large national chains, such as RD Saúde, Grupo DPSP, and Farmácias Pague Menos, hold a substantial market share and are actively expanding their physical footprint and digital presence, leading to fierce competition for market share. [Value Chain Analysis, Industry Research] In 2023, the major chains associated with Abrafarma, representing only about 10% of the total pharmacies, accounted for R$ 91.3 billion in sales and were responsible for 53% of medication dispensations, highlighting the revenue concentration and the impact of these large players. [Value Chain Analysis, Industry Research] This high concentration among leading players intensifies competition, particularly through aggressive pricing strategies and promotional activities, which can pressure margins for all participants, especially smaller independent pharmacies. [Value Chain Analysis] The growth of e-commerce and omnichannel strategies further adds another layer of competition, pushing retailers to invest in technology and logistics to remain competitive. [Value Chain Analysis, 23] The proposed merger between EMS and Hypera Pharma in late 2024, aiming to create Brazil's largest drug manufacturer with a significant market share, could further impact the competitive dynamics at the manufacturing level, potentially increasing their bargaining power with retailers and distributors.
Bargaining Power of Suppliers¶
The bargaining power of suppliers in the Brazilian retail pharmacy value chain, primarily pharmaceutical manufacturers and increasingly, distributors, is considered moderate to high. The manufacturing segment is relatively concentrated, with the top 10 manufacturers accounting for nearly half of sales to retail in 2024. [Value Chain Analysis] Large national laboratories like Grupo NC (EMS), Eurofarma, and Hypera Pharma, as well as multinational corporations such as Pfizer, hold significant influence due to their product portfolios and brand recognition. [Value Chain Analysis, Industry Research] The proposed merger between EMS and Hypera Pharma is expected to enhance the combined entity's bargaining power with downstream players.
However, the bargaining power of manufacturers is somewhat counterbalanced by the increasing consolidation and purchasing power of large retail chains and distributor groups. Large retail chains can negotiate more favorable terms due to the large volumes they purchase. Distributors, handling over half the volume and value flowing to retail, also exert influence through their logistical networks and relationships with numerous pharmacies. [Value Chain Analysis, Industry Research] The reliance on imported Active Pharmaceutical Ingredients (APIs) can also give some leverage to international raw material suppliers. [Value Chain Analysis] Regulatory factors, such as ANVISA's approval processes and CMED's price controls, also influence the dynamics between manufacturers and other players in the chain. [Value Chain Analysis, 9, 10, 18]
Bargaining Power of Customers¶
The bargaining power of customers in the Brazilian retail pharmacy market is high, driven by several factors. Consumers have a vast number of pharmacies to choose from, ranging from large national chains to independent local stores, increasing their price sensitivity and ability to switch between retailers. [Value Chain Analysis, 2] The intense competition among retailers leads to aggressive pricing strategies, discounts, and loyalty programs, further empowering consumers. [Value Chain Analysis] The availability of generic and similar drugs provides consumers with more affordable alternatives to reference drugs, increasing their price consciousness. [4, Value Chain Analysis]
Furthermore, the increasing access to information online and the growth of e-commerce platforms allow consumers to compare prices and services easily, enhancing their negotiation power. [Value Chain Analysis, 23] While individual consumers may have limited power, collectively, their choices significantly influence the market. The growing demand for convenience and expanded health services also gives customers influence over the types of offerings pharmacies provide. [Value Chain Analysis, 15, 22]
Threat of New Entrants¶
The threat of new entrants into the Brazilian retail pharmacy market is considered moderate. While the initial capital investment for establishing a large-scale pharmacy chain with extensive physical presence and logistical capabilities is substantial, making large-scale entry challenging, the high number of existing independent pharmacies suggests that entry at a smaller, local scale is more feasible. [Value Chain Analysis, 2]
However, several factors act as barriers to entry. The complex regulatory environment, including stringent requirements from ANVISA for licensing, operations, and product handling, poses a significant hurdle for new players. [Value Chain Analysis, 9, 10, 14, 25] Established relationships between existing manufacturers, distributors, and retailers create strong networks that can be difficult for new entrants to penetrate. Brand recognition and customer loyalty built by established chains also make it challenging for newcomers to gain market share quickly. [Value Chain Analysis] Despite these barriers, the continued growth and attractiveness of the Brazilian market may still incentivize new players, potentially including international retailers or non-traditional players like large supermarkets or online marketplaces expanding their offerings.
Threat of Substitute Products¶
The threat of substitute products in the Brazilian retail pharmacy market is moderate and evolving. The primary substitutes for traditional pharmacies include other channels for obtaining medications and health products.
One significant substitute is the public health system (SUS), which provides free or subsidized medications to a large portion of the population. [Value Chain Analysis, 9] While this serves a critical public health function, it can reduce the demand for certain products in the private retail channel.
Other retail channels, such as supermarkets, hypermarkets, and convenience stores, offer a range of non-pharmaceutical products typically found in pharmacies, including hygiene, cosmetics, and some OTC products, posing a direct substitute threat for these categories. [Value Chain Analysis]
Online pharmacies and marketplaces are also growing substitutes, offering convenience and potentially lower prices for consumers, particularly for non-prescription items. This threat is increasing with the ongoing digital transformation and changing consumer preferences.
However, for prescription medications, the role of the pharmacist and the need for personalized counseling and verification of prescriptions in a physical or digitally-enabled pharmacy setting remain crucial, limiting the direct substitution by non-pharmacy channels for these essential products. [Value Chain Analysis, 10] The expansion of health services within pharmacies also helps to differentiate them from pure product retailers. [Value Chain Analysis, 15, 22]
Influence of Regulations and Other External Forces (Complementors)¶
Regulations and other external forces, including complementors, exert a significant influence on the Brazilian retail pharmacy value chain.
Regulations: The regulatory environment, primarily governed by ANVISA and CMED, is a dominant force. ANVISA oversees sanitary surveillance, drug registration, manufacturing practices (GMP), distribution, and retail operations, imposing strict requirements throughout the chain. [Value Chain Analysis, 9, 10, 14, 17, 25] CMED is responsible for regulating drug prices, setting maximum price ceilings that impact the profitability of manufacturers, distributors, and retailers. [Value Chain Analysis, 9, 10, 17, 18] Changes in these regulations, such as streamlined marketing authorization processes or adjustments to pricing rules, directly affect market dynamics, operational costs, and profitability. The complex tax system in Brazil also represents a significant external burden, increasing operational costs across all stages. [Value Chain Analysis]
Complementors: Complementors are entities or services that enhance the value of the core retail pharmacy offerings. In the Brazilian context, key complementors include: * Healthcare Professionals: Physicians, dentists, and other healthcare providers who prescribe medications are crucial complementors, driving demand for pharmaceutical products. * Technology Providers: Companies offering e-commerce platforms, logistics software, inventory management systems, and pharmacy automation solutions are becoming increasingly important, enabling pharmacies to improve efficiency and reach customers. * Health Service Providers: Partners who collaborate with pharmacies to offer expanded health services, such as diagnostic labs or telemedicine providers, complement the traditional retail function and enhance the pharmacy's role as a health hub. [Value Chain Analysis] * Financial Institutions: Banks and credit providers that offer credit facilities to distributors and retailers play a vital role in enabling the flow of goods through the value chain. [Value Chain Analysis] * Multisided Platforms: Platforms like FEBRAFAR that connect retailers, manufacturers, and service providers act as important complementors, facilitating interactions and potentially creating new value for participants.
The actions and strategies of these complementors can significantly influence the attractiveness and growth potential of the retail pharmacy market. For example, advancements in telemedicine could increase the demand for pharmacy delivery services, while changes in healthcare reimbursement policies could impact the viability of offering certain health services within pharmacies.
References¶
Abradilan. Crescimento das grandes redes de farmácias. https://abradilan.com.br/crescimento-das-grandes-redes-de-farmacias/ Abradilan. Farmácias destacam-se entre 120 maiores varejistas do Brasil. https://abradilan.com.br/farmacias-destacam-se-entre-120-maiores-varejistas-do-brasil/ Abradilan. Brasil tem 18 indústrias farmacêutica bilionárias. https://abradilan.com.br/brasil-tem-18-industrias-farmaceutica-bilionarias/ Abradilan. Das 20 maiores farmacêuticas do Brasil, 17 são nacionais. https://abradilan.com.br/das-20-maiores-farmaceuticas-do-brasil-17-so-nacionais/ Abradilan. Dez maiores farmacêuticas do Brasil detêm 48,6% das vendas. https://abradilan.com.br/dez-maiores-farmaceuticas-do-brasil-detem-486-das-vendas/ E-Commerce Brasil. Varejo farmacêutico brasileiro soma R$ 158,4 bi em 2024. https://web.archive.org/web/20240523095902/https://ecommercebrasil.com.br/noticias/varejo-farmaceutico-brasileiro-soma-r-158-4-bi-em-2024 Estadão RI. Principais redes de farmácias faturaram R$ 91,3 bi em 2023. https://web.archive.org/web/20240509012914/https://conteudo.estadao.com.br/system/public/estadaori/2024/04/29/principais-redes-de-farmacias-faturaram-r913-bi-em-2023.html Giro News. Redes de farmácias faturaram R$ 91,3 bilhões em 2023; RD segue no topo do ranking. https://web.archive.org/web/20240520122416/https://gironews.com/farma-cosmeticos/redes-de-farmacias-faturaram-r913-bilhoes-em-2023-rd-segue-no-topo-do-ranking/ InovaFarma. Confira os números atualizados do mercado de varejo farmacêutico no Brasil. https://web.archive.org/web/20240523095025/https://onovovarejo.com.br/inovafarma-numeros-atualizados-mercado-varejo-farmaceutico-brasil/ Investe SP. Brasil soma 47% do mercado farmacêutico na América Latina. https://web.archive.org/web/20240517191733/https://www.investe.sp.gov.br/noticia/brasil-soma-47-do-mercado-farmaceutico-na-america-latina Novo Varejo. Conheça as 5 maiores redes de farmácia do Brasil. https://web.archive.org/web/20240523100517/https://onovovarejo.com.br/5-maiores-redes-de-farmacia-brasil/ Panorama Farmacêutico. Ranking das grandes redes de farmácias da Abrafarma. https://web.archive.org/web/20240523094400/https://panoramafarmaceutico.com.br/ranking-grandes-redes-farmacias-abrafarma-2024/ Panorama Farmacêutico. Redes de farmácias mantêm projetos de expansão para 2024. https://web.archive.org/web/20240523095253/https://panoramafarmaceutico.com.br/redes-de-farmacias-mantem-projetos-de-expansao-para-2024/ Panorama Farmacêutico. Ranking das redes de farmácias mostra consolidação do setor. https://web.archive.org/web/20240523095536/https://panoramafarmaceutico.com.br/ranking-redes-de-farmacias-mostra-consolidação-do-setor/ Pague Menos tem receita bruta de R$3,1 bi no 1T24. https://web.archive.org/web/20240523100844/https://agenciabrasil.ebc.com.br/economia/noticia/2024-05/pague-menos-tem-receita-bruta-de-r31-bi-no-1t24 Value Chain Analysis - Value Chain Report on the Retail Pharmacy Industry in Brazil. Industry Research - Industry Research Report on the Retail Pharmacy in Brazil. Grandes redes farmacêuticas esperam faturamento de R$ 100 bilhões em 2024. https://web.archive.org/web/20240521005047/https://www.bnews.com.br/noticias/economia/grandes-redes-farmaceuticas-esperam-faturamento-de-r-100-bilhoes-em-2024.html